AMPH vs DXCM: fair value comparison
Amphastar Pharmaceuticals, Inc. and DexCom, Inc. · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AMPH currently sits closer to the top of our discount ranking. DXCM carries the stronger quality grade.
| AMPH | DXCM | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $20.22 | $87.90 |
| 12-month range | $18.42–$27.92 | $58.22–$90.14 |
| Sector rank | #15 of 113 Healthcare | #20 of 113 Healthcare |
| Quality grade | C- | A |
| Momentum grade | A | A |
| Leverage | Moderate | Moderate |
| Margin trend | — | Contracting |
| Revenue growth | — | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Uptrend |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: AMPH fair value analysis · DXCM fair value analysis